Rob Freelen is a Managing Director in Silicon Valley Bank’s Life Sciences Practice where he leads new business development on the West Coast.
Since joining SVB in 2005 Rob has worked on hundreds of deals, having led debt transactions for companies including:
-Affymax Pharma (NASDAQ: AFFY)
-Complete Genomics (NASDAQ: GNOM, Acquired by BGI-Shenzhen)
-Concentric Medical (Acquired by Stryker)
-DexCom (NASDAQ: DXCM)
-Hyperion Therapeutics (NASDAQ: HPTX)
-Veracyte (NASDAQ: VCYT)
Prior to joining Silicon Valley Bank Rob held business development roles with asset management firm Fisher Investments and internet marketing start-up Impower Inc. Rob earned a B.A. from Whitman College in Walla Walla, WA.
Rob spends his free time working with the Silicon Valley Cycling Foundation and Ravenswood Family Health Clinic when he's not chasing his two young daughters through the Silicon Valley.
Palo Alto, CA
Medical Device, Biotechnology, Diagnostics, Drug Development, Life Sciences Venture Capital
T 650 320 1168